Company intelligence / Profile preview

M's Science Corporation

Kobe, Japanmarvelousmsmscience.weebly.com ↗

Ownership: Private
Development stage: Other

Overview

The company has developed two programs that have progressed to clinical trial stages with satisfactory results: a sigma-1 receptor agonist for CNS diseases and an attenuated live herpes simplex virus for solid tumors (which was sold in 2010)[2]

Therapeutic areas: OphthalmologyOncologyNeurology
Modalities: Small molecules (sigma-1 receptor agonists)Attenuated live herpes simplex virus (previously)
Industry: Biotech

Drug pipeline

2 assets

cutamesine

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on M's Science Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M's Science Corporation.

Explore the full profile